Report for: Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent*

Title	Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent*
Published in	Anais Brasileiros de Dermatologia, January 2015
DOI	10.1590/abd1806-4841.20153408
Pubmed ID	26312673
Authors	Maria Victória Quaresma, Fred Bernardes, Janaína Hezel, Murilo Calvo Peretti, Bernard Kawa Kac, Luna Azulay-Abulafia
Abstract	Pemphigus vulgaris is an autoimmune disease characterized by suprabasal blisters with acantholysis, which has a fatal course in a large number of untreated patients. Systemic corticosteroid therapy is considered first-line therapy. Adjuvant treatment with the goal of sparing corticosteroids include, among others, dapsone. This drug is not without side effects and its use requires clinical and laboratory control. We present a patient with PV initially managed with suboptimal dose of prednisone, evolving into drug-induced hepatitis after introduction of dapsone.

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Germany	1	100%

Type	Count	As %
Members of the public	1	100%

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	25	100%

Readers by professional status	Count	As %
Student > Postgraduate	6	24%
Other	4	16%
Student > Bachelor	3	12%
Student > Master	2	8%
Unspecified	1	4%
Other	2	8%
Unknown	7	28%

Readers by discipline	Count	As %
Medicine and Dentistry	14	56%
Biochemistry, Genetics and Molecular Biology	2	8%
Neuroscience	1	4%
Unspecified	1	4%
Unknown	7	28%

Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent*